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The endothelium is a regulatory organ that medi- 
ates hemostasis, contractilii, cellular prolttra- 
tion, and inflammatory mechanisms in the vessel 
wall. Injury to the endothelium from hyperten- 
sion, smoking, hyperlipklemia, and diabetes mel- 
litus disrupts normal regulatory properties and 
results In abnormal endothelial cell function. Clin- 
ically, endothelial cell dysfunction can be mani- 
fested as vasospasm, thrombus formation, ath- 
erosclerosis, or restenosis. The normal 
hemostatic properties of the endothelium include 
the maintenance of a nonadhesive luminal sur- 
face, antithrombotic properties, anticoagulant 
properties, and fibrinolytk propertii. The endo- 
thelial cell regulates smooth muscle cell contrac- 
tilii by the production of relaxing and constrict- 
ing factors in response to physiologic stimuli. 
Endothelial cell injury is also an initial event in 
the development of atherosclerosis and resteno- 
sis by facilttthrg platelet adhesion and aggrega- 
tion and by signaling the release of mttogens 
from platelets, macrophages, and endothelial 
cells, which stimulate smooth muscle cell prollf- 
e&ion. In addition, endothelial cells undergo 
morphologk and functional alterations in re- 
sponse to cytokine signals, which may contribute 
to the pathogenesis of vascuiitis and atheroscle- 
rosis. In sum, the normal endothelium performs 
many regulatory functions which become altered 
when the endothelium is injured. 
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T he normal endothelium maintains a nonad- hesive luminal surface and has fibrinolytic, anticoagulant, and antithrombotic proper- 
ties [1,2]. A normal endothelial surface prevents 
the attachment of platelets. Platelet aggregation 
and adhesion are also normally inhibited by endo- 
thelial cell synthesis of prostacyclin (prostaglandin 
I,) and endothelium-derived relaxing factor 
(EDRF) [3,4]. Antithrombotic and fibrinolytic prop- 
erties of the endothelium are regulated by basal 
synthesis of tissue-type plasminogen activator 
(t-PA), which stimulates lysis of fibrin clots. Anti- 
thrombotic properties in the vessel wall are regu- 
lated through synthesis of antithrombin III, which 
binds to and inactivates thrombin, factor X, and 
other serine proteases [5]. Anticoagulant proper- 
ties in the vessel wall are regulated by several 
pathways. The principal anticoagulant action of 
the endothelium is mediated through protein C 
and protein S [6]. The binding of thrombin to 
thrombomodulin serves to activate protein C; the 
latter, in turn, blocks factors Va and VIIIa. Anti- 
thrombin III inactivates thrombin and factor Xa, as 
well as endothelial cell serine proteases. The throm- 
bin-thrombomodulin complex inactivates the pro- 
coagulant properties of thrombin, such as platelet 
activation. In addition, endothelial cell production 
of heparin-like glycosaminoglycans catalyzes the 
inactivation of coagulation proteases such as throm- 
bin and factor X [7]. 
HEMOSTASIS 
Normal hemostasis is disrupted when the vessel 
is injured. Subendothelial (collagen matrix) base- 
ment membrane is exposed. von Willebrand’s fac- 
tor is activated by thrombin to facilitate platelet 
adhesion and aggregation. Platelet-activating fac- 
tor also contributes to primary hemostasis. Endog- 
enous thrombolysis (t-PA) is inhibited by plasmino- 
gen activator inhibitor. Endothelial cell disruption 
also exposes tissue factor VII, which activates the 
extrinsic coagulation pathway, as well as factor XII, 
which stimulates the intrinsic coagulation pathway. 
Endothelial cell serine proteases also facilitate 
thrombus formation. 
Endothelial cell injury stimulates primary hemo- 
6c THE AMERICAN JOURNAL OF CARDIOLOGY VOLUME 68 NOVEMBER 4, 1991 
stasis by several mechanisms. Platelet adhesion 
occurs when platelets bind to the subendothelium 
via the platelet collagen receptor glycoprotein IA 
and to basement membrane by interactions with 
van Willebrand’s factor and the glycoprotein IB 
receptor. Platelet aggregation follows when plate- 
lets bind to other platelets via the platelet glycopro- 
tein receptor IIB IIIA. Platelet degranulation re- 
sults in the release of vasoactive proteins from (Y 
granules, such as adenosine diphosphate (ADP), 
serotonin, thromboxane A,, thrombin, and hista- 
mine, which further promote platelet aggregation, 
vasoconstriction, leukocyte chemostasis, and forma- 
tion of a hemostatic plug. 
coNTRAcTllmY 
The healthy endothelium regulates vascular con- 
tractility and promotes vascular relaxation. The 
endothelium contains receptors for various pharma- 
cologic stimuli, including thrombin, vasopressin, 
acetylcholine, and platelet granulation products 
[8]. Receptor binding stimulates endothelial cell 
synthesis and release of EDRF, which acts locally 
on smooth muscle cells to stimulate production of 
cyclic guanosine monophosphate (cGMP) which, 
in turn, mediates relaxation [9]. Although more 
investigation is needed, there is convincing evi- 
dence that EDRF encompasses a group of sub- 
stances, one of which is probably nitrous oxide 
[9,10]. Other non-receptor-mediated stimuli, such 
as shear stress and calcium ionophore, also initiate 
EDRF release [Ill. Endothelial cells promote 
smooth muscle cell relaxation through the local 
production of prostacyclin which causes an in- 
crease in cyclic adenosine monophosphate (CAMP), 
resulting in vasodilation. 
These vasodilator mechanisms are counter- 
balanced by vasoconstrictor substances produced 
by the endothelium. For example, endothelin is a 
potent vasoconstrictor produced by the endothelial 
cells in response to hypoxia and other stimuli [12]. 
The exact physiologic role of endothelin in normal 
and atherosclerotic conditions is now under evalu- 
ation. 
A complex series of events occurs when the 
endothelium is injured. Since receptor-mediated 
stimulation of EDRF is disrupted, physiologic and 
pharmacologic stimuli produce a direct effect on 
smooth muscle cells, resulting in vasoconstriction. 
For example, vasoconstriction is routinely ob- 
served following coronary angioplasty [13]. Vaso- 
spasm surrounding an atherosclerotic plaque may 
occur due to deficient release of EDRF, and 
probably accounts for some angina experienced by 
patients with coronary artery disease. 
CELLULAR PROIJFERATION 
Injury to the endothelium may initiate the 
development of atherosclerosis [14]. Circulating 
monocytes adhere to the injured vessel surface and 
migrate into the intima, take up extracellular lipid 
as macrophages, and develop into foam cells. 
Growth factors, released by platelets, endothelial 
cells, and macrophages, promote smooth muscle 
cell migration into the intima and proliferation. 
Macrophages and proliferating smooth muscle cells 
engage in collagen matrix synthesis. Abnormal 
cellular proliferation, in combination with calcium 
deposition and thrombus formation, results in the 
development of an atherosclerotic plaque. Balloon 
injury following angioplasty initiates a similar pro- 
cess of pathologic cellular proliferation, which 
becomes manifest over several months as resteno- 
sis [15]. Release of mitogens by activated endothe- 
lium, platelets, and mononuclear cells may be 
associated with a change in medial smooth muscle 
cells. The smooth muscle cell is normally refractory 
to growth factors and does not synthesize collagen 
matrix. When the blood vessel is injured, the 
smooth muscle cell may undergo a ‘phenotypic’ 
change to a synthetic cell where it becomes noncon- 
tractile, responsive to growth factors, and capable 
of connective tissue synthesis [16]. 
IMMUNITY AND INFkAMMATIiON 
The endothelium is responsive to a number of 
cytokines, including the interferons ((x, l3, and X), 
tumor necrosis factor-a, interleukin-1, and interleu- 
kin-6 [17]. These products of the immune system 
can induce changes in endothelial cell structure 
and function by a process termed endothelial 
activation. Endothelial cells become activated by 
the binding of leukocytes, monocytes, and lympho- 
cytes to the endothelium by adhesion molecules. 
For example, interleukin-1 can induce the synthe- 
sis of endothelial leukocyte adhesion molecule-l 
(ELAM-l), which stimulates neutrophil adhesion 
to endothelial cells [18]. Interferon-A stimulates 
intracellular adhesion molecule 1 (ICAM-1) expres- 
sion, which in turn promotes lymphocyte attach- 
ment and a local immune response. The adhesion 
of mononuclear cells to endothelial cells by adhe- 
sion molecules is a process that is central to 
vascular inflammation and a response to immune 
injury [19,20]. These mechanisms may also be 
responsible, in part, for the accelerated atheroscle- 
rosis observed in cardiac transplant arteries. 
A SYMPOSIUM: MECHANISMS OF UNSTABLE ANGINA 7c 
In conclusion, the endothelium is a highly active 
and reactive tissue that regulates hemostasis, vascu- 
lar contractility, cellular proliferation, and immu- 
nity and inflammation. As our understanding of 
the endothelium expands, new therapeutic modali- 
ties are likely to emerge, based on recombinant 
DNA technology [21,22]. 
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